3O8 Stock Overview A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Omeros Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Omeros Historical stock prices Current Share Price US$9.42 52 Week High US$12.39 52 Week Low US$2.52 Beta 1.99 1 Month Change -8.33% 3 Month Change 178.06% 1 Year Change 246.14% 3 Year Change 72.18% 5 Year Change -20.88% Change since IPO 104.23%
Recent News & Updates
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting Dec 11
Omeros Corporation Provides Update on Progress Toward BLA Resubmission Nov 21
Omeros Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 12
FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy Oct 26
New major risk - Financial position Aug 08
Omeros Corporation to Report Q2, 2024 Results on Aug 07, 2024 Aug 06 See more updates
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting Dec 11
Omeros Corporation Provides Update on Progress Toward BLA Resubmission Nov 21
Omeros Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 12
FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy Oct 26
New major risk - Financial position Aug 08
Omeros Corporation to Report Q2, 2024 Results on Aug 07, 2024 Aug 06
Omeros Corporation Announces Executive Changes Jun 14 Omeros Corporation announced that it expects to receive $92.1 million in funding Jun 05
Omeros Corporation to Report Q1, 2024 Results on May 15, 2024 May 12
Omeros Corporation, Annual General Meeting, Jun 06, 2024 May 01 Omeros Corporation (NasdaqGM:OMER) announces an Equity Buyback for $50 million worth of its shares. Apr 02
Omeros Corporation to Report Q4, 2023 Results on Apr 01, 2024 Mar 28
New major risk - Negative shareholders equity Nov 10
Omeros Corporation to Report Q3, 2023 Results on Nov 09, 2023 Nov 07
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting Nov 03
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer Oct 20
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy Oct 17
New minor risk - Market cap size Oct 17
Omeros Corporation to Report Q2, 2023 Results on Aug 09, 2023 Aug 05 Omeros Corporation, Annual General Meeting, Jun 23, 2023 Kurt Zumwalt Not to Stand for Re-Election as Class II Director of Omeros Corporation May 18
Omeros Corporation to Report Q1, 2023 Results on May 09, 2023 May 05
No longer forecast to breakeven Mar 15
Insufficient new directors Nov 16
Omeros Corporation to Report Q3, 2022 Results on Nov 09, 2022 Nov 05 Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab Aug 18
Omeros Corporation to Report Q2, 2022 Results on Aug 09, 2022 Aug 05
First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.57 loss in 1Q 2021) May 11
Omeros Corporation to Report Q1, 2022 Results on May 10, 2022 May 05
No longer forecast to breakeven May 03
Omeros Corporation, Annual General Meeting, Jun 17, 2022 May 03
Insufficient new directors Apr 27
Insufficient new directors Apr 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 03
Insufficient new directors Mar 02
Omeros Corporation to Report Q4, 2021 Results on Mar 01, 2022 Feb 25
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA Jan 20
Forecast to breakeven in 2024 Jan 01
Rayner Surgical Inc. completed the acquisition of OMIDRIA Franchise from Omeros Corporation (NasdaqGM:OMER). Dec 24
Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020) Nov 10
Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.61 loss in 2Q 2020) Aug 11
Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentation at 2021 Annual Congress of the European Hematology Association Jun 15
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906 Jun 10
Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab May 29
Omeros Corporation Announces Extension of U.S. Food and Drug Administration Review Period for Narsoplimab in HSCT-TMA May 21
Omeros Corporation Announces Data on Organ Function Improvement from Omeros’ Pivotal Trial of Narsoplimab for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy May 14
First quarter 2021 earnings released: US$0.57 loss per share (vs US$0.54 loss in 1Q 2020) May 11
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration May 05
Full year 2020 earnings released: US$2.42 loss per share (vs US$1.71 loss in FY 2019) Mar 02
Revenue misses expectations Mar 02
Omeros Corporation to Report Q4, 2020 Results on Mar 01, 2021 Feb 26
New 90-day high: €18.15 Feb 11
Omeros Corporation Appoints Nadia Dac as Its Chief Commercial Officer Jan 28
New 90-day high: €16.20 Jan 26
Omeros Corporation Announces Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA Jan 20
New 90-day high: €12.40 Jan 07
Omeros Corporation Announces Centers for Medicare & Medicaid Services Confirm Separate Payment for Omeros’ FDA-Approve OMIDRIA in Ambulatory Surgery Centers Dec 04
New 90-day high: €11.37 Dec 04
Omeros Corporation Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA Nov 19
Third quarter 2020 earnings released: US$0.66 loss per share Nov 11
Revenue beats expectations Nov 11
Omeros Corporation to Report Q3, 2020 Results on Nov 09, 2020 Nov 06
Omeros Corporation to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA Oct 16
New 90-day low: €8.04 Sep 29
Omeros Corporation has completed a Follow-on Equity Offering in the amount of $100.05 million. Aug 13
First half earnings released Aug 11
New 90-day low - €11.27 Jul 30 Shareholder Returns 3O8 DE Pharmaceuticals DE Market 7D -10.7% 2.2% 0.7% 1Y 246.1% -16.8% 8.4%
See full shareholder returns
Return vs Market: 3O8 exceeded the German Market which returned 8.4% over the past year.
Price Volatility Is 3O8's price volatile compared to industry and market? 3O8 volatility 3O8 Average Weekly Movement 26.9% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 3O8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3O8's weekly volatility has increased from 17% to 27% over the past year.
About the Company Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders.
Show more Omeros Corporation Fundamentals Summary How do Omeros's earnings and revenue compare to its market cap? 3O8 fundamental statistics Market cap €557.89m Earnings (TTM ) -€180.63m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 3O8 income statement (TTM ) Revenue US$0 Cost of Revenue US$69.78m Gross Profit -US$69.78m Other Expenses US$115.60m Earnings -US$185.37m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.20 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -268.2%
How did 3O8 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 05:02 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Omeros Corporation is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gregory Harrison BofA Global Research Jason Kolbert B. Riley Wealth Ritu Baral Canaccord Genuity
Show 18 more analysts 
